Neurocrine Biosciences (NASDAQ:NBIX) dropped by -3.63 or -1.61 points during the last session to $42.71 per share. One of the highlights of the day was the net money flow figure, which stood at $2.65 million even as the stock accepted $14.27 million in upticks but rejected $11.62 million in downticks. The up/down ratio for the last observation was a 1.23. The 1-week percentage change for the stock price is registered at -3.46%.A block transaction occurred with $2.12 million in upticks and $0 million in downticks while the up/down ratio was calculated to be 0. The stock witnessed a net inflow of $2.12 million at the end of the block trade.
The stock has recorded a 20-day Moving Average of 11.28% and the 50-Day Moving Average is 8.43%. The company shares have dropped 9.07% in the past 52 Weeks. On November 27, 2015 The shares registered one year high of $58.46 and one year low was seen on February 9, 2016 at $31.25. The 50-day moving average is $46.61 and the 200 day moving average is recorded at $44.3. S&P 500 has rallied 1.93% during the last 52-weeks.
Neurocrine Biosciences (NASDAQ:NBIX): The stock opened at $44.59 on Tuesday but the bulls could not build on the opening and the stock topped out at $44.86 for the day. The stock traded down to $41.70 during the day, due to lack of any buying support eventually closed down at $42.71 with a loss of -3.63% for the day. The stock had closed at $44.32 on the previous day. The total traded volume was 1,549,019 shares.
Currently the company Insiders own 4.8% of Neurocrine Biosciences shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -24.89% . During last six month period, the net percent change held by insiders has seen a change of -24.89%. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Lloyd-Smith Malcolm, officer (Chief Regulatory Officer) of Neurocrine Biosciences Inc, had unloaded 9,000 shares at an average price of $50 in a transaction dated on May 31, 2016. The total value of the transaction was worth $450,000.
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Companys two lead late-stage clinical programs are elagolix, a gonadotropin releasing hormone (GnRH) antagonist for womens health that is partnered with AbbVie Inc. (AbbVie), and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective, orally-active, non-peptide CRF receptor antagonist.